Exchange: NASDAQ·Updated 01:21 AM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 10Pre-Market

Estimated EPS

$0.00

Estimated Rev

$42.19M

$HRTX Q1 '26 Earnings Results & Recap Heron Therapeutics reported Q1 2026 net product sales of $34.7M, yielding an $8.1M net loss or $0.04 per share; acute care sales rose $3.3M, while oncology sales decreased -$7.5M.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.00
--
--
N/A
Q1 '26
-$0.02
-$0.04
-71.43%
MISSED
Q4 '25
-$0.02
-$0.02
--
EXPECTED
Q3 '25
-$0.01
-$0.10
-566.67%
MISSED
Q2 '25
-$0.01
-$0.02
-100.00%
MISSED

Advertisement|Remove ads.